RapidAI Receives FDA 510(k) Clearance for Rapid PE Triage & Notification System

May 24, 2022—RapidAI announced that its Rapid Pulmonary Embolism (PE) Triage & Notification product received FDA 510(k) clearance for the fast identification and communication of suspected central PE.

According to the company, Rapid PE Triage & Notification works with the Rapid Workflow for PE and enables care teams to manage the entire patient care journey more easily. The system can automatically identify a suspected PE and deliver real-time notifications to physicians, which allows patients to be triaged faster and care teams aligned more quickly, reducing overall time to treatment.

“I’m excited to see first-hand how artificial intelligence will transform the way we triage and manage PE, a historically complicated process involving a diverse care team,” commented Jimmy Kerrigan, MD, in the company’s announcement. “After seeing what RapidAI technology has done for stroke, I’m optimistic about its potential to optimize our care for patients and to hopefully improve patient outcomes.” Dr. Kerrigan is an interventional cardiologist at Ascension Saint Thomas Heart in Nashville, Tennessee.

“Building on our expertise in stroke, we’re confident this technology will help modernize PE care and meaningfully improve patient outcomes,” said Karim Karti, CEO of RapidAI. “Our goal is to build solutions that address the specific challenges associated with treating various conditions, as well as the communication and workflow issues faced by hospitals globally.”